TVGN TEVOGEN BIO HOLDINGS INC

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

WARREN, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today announced that, following the Company’s recent press release highlighting the Direct Registration System (DRS) as a secure method of share ownership, it has received a number of inquiries from shareholders seeking additional information on how to transfer their shares to a DRS account.

In response, Tevogen will provide step-by-step guidance early next week to help interested shareholders register their shares directly with the Company’s transfer agent, Continental Stock Transfer & Trust.

The Company also notes that several of its largest shareholders, both internal and external, have elected to hold their shares via DRS, underscoring their confidence in this method of direct ownership.

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701



EN
02/05/2025

Underlying

TVGNTEVOGEN BIO HOLDINGS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TEVOGEN BIO HOLDINGS INC

 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patient...

Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow WARREN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced a planned expansion of TVGN 489’s target population to include patients 65 and older. , the top-line revenue forecast for the specialty care pipeline was projected at nearly $1 billion in its launch year, with a cumulative five-year estimate ranging between $18 billion and $22 billion. This anticipated expan...

May 23, 2025 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Part...

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting WARREN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that it will provide several updates to stockholders in advance of the Company’s upcoming Annual Meeting of Stockholders scheduled for June 23, 2025. These updates will provide content regarding the Company’s innovative business model and strategic growth initiatives, which management ...

May 22, 2025 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges w...

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ). As the biopharma industry faces increasing competition from international markets and an evolving regulatory landscape, Tevogen Bio’s innovative business model positions it as a potential leader in the shift towards cost-efficient, value-driven healthcare. With the concern of Chinese pharmaceutical companies developing drugs at a faster pace and lower cost, the U.S. biotech sector faces p...

May 12, 2025 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen to Share Direct Registration System (DRS) Process Details Foll...

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest WARREN, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today announced that, following the Company’s recent press release highlighting the Direct Registration System (DRS) as a secure method of share ownership, it has received a number of inquiries from shareholders seeking additional information on how to transfer their shares to a DRS account. In response, Tevogen will provide step-by-step guidance early next week to help interested s...

May 2, 2025 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manuf...

CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment WARREN, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today announced that CD8 Technology Services LLC (“CD8”) has signed a letter of intent for a facility designed to support Tevogen Bio’s cell therapy manufacturing facility. Tevogen Founder and CEO, Ryan Saadi, MD, MPH commented, “In-house manufacturing is critical to our operational efficiency, and with 74% insider ownership, we place the highest ...

April 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch